AlphAIAlphAI — Financial news for AI agents
yahoo.comAUG 212 min read$MXCT

MaxCyte (MXCT) Q2 2026 Earnings Call Transcript

MaxCyte (MXCT) reported Q2 2026 revenues ahead of expectations, with sequential growth driven by instrument placements, including its DTx platform. The company reduced net loss YoY and announced a multiplatform technology license partnership with Genentech, reflecting growing recognition of MaxCyte's technology. The partnership supports multiple programs and diversifies MaxCyte's revenue streams. Vertex's CASGEVY revenue grew 75% sequentially and 150% YoY, contributing to MaxCyte's SPL program-r

Original reporting
yahoo.com
Published Aug 21, 2026, 11:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$MXCTNeutralLow
01

Why it matters

The call offers limited new data; investors may watch for future guidance updates.

02

Market read

Primarily relevant to biotech investors tracking MaxCyte's partnership strategy.

03

What to watch

Potential long‑term revenue diversification from enterprise‑level deals.

Relevance 4/10Novelty 3/10Timing: post‑earnings call

Background

MaxCyte discussed Q2 performance, strategic initiatives, and a new enterprise partnership with Genentech.

Company-level read

Ticker impact

$MXCTNeutralMedium confidence
Context

Q2 2026 earnings call transcript provides qualitative updates on revenue growth, loss reduction and a new partnership with Genentech.

Expected impact

Limited immediate impact; potential modest upside if partnership drives future revenue.

Evidence & confidence

No new quantitative guidance; only strategic partnership announcement.

Market effects

Sector

Highlights growing collaboration between cell‑therapy platform providers and large pharma.

Regional

U.S. biotech sector may see modest interest.

Global

Limited; partnership is company‑specific.

Counterpoint

What could challenge this read

Without concrete financial guidance, the partnership may not translate into near‑term price gains.

Key entities

  • Company
    MaxCyte

    Cell‑therapy technology provider.

  • Company
    Genentech

    Large biopharma partner.

Read at source← All news

Related articles

OCT 14
$MXCTMed

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, MD, October 14, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-en

SEC EDGAR 8-K2 min
AUG 14
Med

MaxCyte, Inc. Q2 2026 Earnings Call Summary

MaxCyte reported Q2 2026 sequential revenue growth after inventory drawdowns from a major customer and clinical program discontinuations. It signed a multi-platform enterprise partnership with Genentech and expects 2026 revenue guidance of $30m to $32m. Operating expenses fell 25% YoY. Company plans to use most of a $10m share repurchase program and expects mid-70s gross margins.

yahoo.com6 min
AUG 12
$MXCTMedAI 8/10

MaxCyte narrows Q2 2026 loss 28%, signs Genentech deal

MaxCyte Inc (NASDAQ: MXCT) reported Q2 2026 EPS of $(0.08), better than the $(0.09) consensus, and revenue of $7.271M versus $6.475M consensus. Sales fell 14.53% year over year. The company signed a multi-platform technology license partnership with Genentech and reiterated 2026 guidance for $30M to $32M revenue.

scanx.trade5 min
AUG 12
$MXCTMed

MaxCyte Reports Second Quarter 2026 Financial Results

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reiterates Full Year 2026 Guidance · Repurchased a

SEC EDGAR 8-K6 min
OCT 14
$ASMLHighAI 8/10

ASML (ASML) Q3 2026 Earnings Call Transcript

ASML reported Q3 2026 earnings with €3.3B in installed base management sales, exceeding guidance. Gross margin was 57.5%, and net income was €5.0B, including a €500M gain from Mistral AI. Free cash flow was €11.4B. ASML expects Q4 sales of €14.2B–€15.2B and full-year 2026 sales of €44B–€45B, with strong demand for EUV and DUV products.

finance.yahoo.com3 min